Vertex Is Buying Crinetics for $10 Billion. Here's What Investors Need to Know.
Yahoo Finance ·
Vertex Pharmaceuticals ( VRTX 1.31% ) is making its biggest bet in years. On Monday, the company agreed to acquire Crinetics Pharmaceuticals ( CRNX +98.74% ) for $85 per share in cash. That works out to a total equity value of about $10 billion, or roughly $8.8 billion net of the cash Crinetics holds. Both companies' boards approved the deal unanimously, and Vertex expects it to close in the third quarter of 2026. For a company that has spent decades built almost entirely around cystic fibrosis, this is a meaningful step into a new disease area. Here's what the deal buys, how Vertex is paying for it, and whether the price looks reasonable. Perhaps the biggest asset Crinetics brings is a drug called PALSONIFY -- the first and only once-daily oral therapy approved for adults with acromegaly. It won U.S. approval in September 2025 and was recently cleared in Europe. Vertex says its early launch has shown strong demand across patient groups. Until PALSONIFY arrived, most patients relied on large-needle injectable treatments, so an oral option fills a real gap. Behind it sits atumelnant, a once-daily oral drug in late-stage development for congenital adrenal hyperplasia, another rare endocrine condition. The drug has also shown early promise in Cushing's syndrome.
DYAX Investor Sentiment
Bullish (Long) 53% · Bearish (Short) 47%
269 participants
Related News
- Prologis urges SEGRO board to engage on merger proposal
- TotalEnergies divests 170 MW European distributed solar portfolio to Amarenco and AMPYR
- Billionaire Steve Cohen Sold Amazon and Nvidia but Loaded Up on This Beaten-Down Stock
- SpaceX Lost $4.28 Billion on $4.7 Billion in Revenue Last Quarter. Here's What's Going On.
- Aimei Health drops 30% after terminating United Hydrogen merger deal
- The Bull Case For Bank of America (BAC) Could Change Following Its Push To Control More Payment Rails